Effects of glycogen synthase kinase 3 inhibitors on the proliferation and apoptosis of chronic myelogenous leukemia K562 cells induced by imatinib / 白血病·淋巴瘤

Objective:To explore the effects of glycogen synthase kinase 3 (GSK3) inhibitors on the proliferation and apoptosis of chronic myelogenous leukemia (CML) K562 cells induced by imatinib.Methods:K562 cells were treated with 1 μmol/L imatinib combined with GSK3 inhibitor lithium chloride with different concentrations of 1.0, 2.0, 4.0 mmol/L, SB216763 with different concentrations of 0.5, 1.0, 5.0 μmol/L andTWS119 with different concentrations of 0.5, 1.0, 5.0 μmol/L, and then 1μmol/L imatinib was used as the control group. The proliferation activity of K562 cells was determined by using CCK8 assay. Flow cytometry was used to detect the cell apoptosis. The level changes of Wnt-β-catenin pathway related-protein were analyzed by using Western blot.Results:There were statistically significant differences of K562 cell survival rate between 1 μmol/L imatinib combined with different concentrations of SB216763, lithium chloride, TWS1193 groups and the control groups (all P < 0.01). The cell survival rate of 1 μmol/L imatinib + 1.0 μmol/L SB216763 group, 1 μmol/L imatinib + 5.0 μmol/L SB216763 group was (73.6±3.0)%, (77.0±3.6)%, which was higher than that of the control group [(68.0±2.8)%], and the difference was statistically significant (both P < 0.05). The cell survival rate of 1 μmol/L imatinib + 0.5 μmol/L SB216763 group was (70.0±2.2)%, and there was no statistical difference between 1 μmol/L imatinib + 0.5 μmol/L SB216763 group and the control group ( P > 0.05). The cell survival rate of 1 μmol/L imatinib + 2.0 mmol/L lithium chloride group and 1μmol/L imatinib + 4.0 mmol/L lithium chloride group was (75.5±3.6)%, (83.4±3.9)%, which was higher than that of the control group [(69.5±2.1)%], and the difference was statistically significant (both P < 0.05); there was no statistical difference in the cell survival rate of 1 μmol/L imatinib + 1.0 mmol/L lithium chloride group [(72.3±6.0)%] and the control group ( P > 0.05). The cell survival rate of 1 μmol/L imatinib combined with 0.5, 1.0, 5.0 μmol/L TWS119 was (70.0±1.1)%, (72.1±0.8)%, (73.8±0.7)%, respectively, which was higher than that of the control group [(67.9±7.5)%] (all P < 0.01). The cell apoptosis rate of 1 μmol/L imatinib + 5.0 μmol/L SB216763, 1 μmol/L imatinib + 4.0 mmol/L lithium chloride, 1 μmol/L imatinib + 5.0 μmol/L TWS119 was (18.16±3.59)%, (20.11±2.98)%, (16.27±2.36)%, respectively, which was lower than that of the control group [(28.26±2.20)%], and the difference was statistically significant (all P < 0.05). Compared with the imatinib group alone, there was no statistical difference in the protein expression levels of t-GSK3β, t-GSK3α of K562 cells treated with imatinib combined with GSK3 inhibitors, while the protein expression levels of p-GSK3β, p-GSK3α, β-catenin were increased. Conclusion:GSK3 inhibitors could reduce the effect of imatinib on the proliferation and apoptosis of CML K562 cells through regulating the related-protein level of Wnt-β-catenin pathway.

Plasma gelsolin levels in prediction of prognosis of ST-segment elevation myocardial infarction / 中国介入心脏病学杂志

Objective To investigate the predictive value of plasma gelsolin in the prognosis of patients with ST-sgement elevation myocardial infarction ( STEMI ) and undergone primary percutaneous coronary intervention ( PCI ) .Methods The study included 206 patients with STEMI and undergone primary PCI, 148 patients with stable angina pectoris and received elective PCI and 80 healthy volunteer as the health population (NP) control.Blood samples were taken at admission on day 1, 3, 5, 7 and 9 to determine the plasma gelsolin level .Patients′baseline clinical characteristics , blood biochemistry tests results , details of operation and their cardiovascular risk factors were recorded .Major adverse cardiovascular events (MACE) within one year were recorded.Results (1) Compared to the stable angina group and the NP group, the level of plasma gelsolin of STEMI patients were obviously decreased at various time points ( all P<0.05 ) .There were no statistical differences between the stable angina group and the NP group .( 2 ) Patients with STEMI were catagorized into MACE group (n=78) and non-MACE group (n=128) according their follow up record in 1 year.The level of plasma gelsolin in patients with MACE were lower than the non-MACE group ( P <0.05 ) with the minimum value detected on day 7.Among patients complicated with MACE (n=78), they were further devided into the deceased group (n=18) and the survival group (n=60).Plasma gelsolin levels were lower in the deceased group with satistical differences found on day 5, 7 and 9.(3) Single factor Logistic regression analysis showed that the level of plasma gelsolin on day 7 was independent risk factor of MACE within one year ( P =0.014 ) .( 4 ) Setting the cutoff value of plasma gelsolin on day 7 as 21.7 mg/L,the sensitivity and speciticity for the MACE in STEMI patients treated with primary PCI within one year were 82.1%and 81.4%respectively , with the area under the receiver operator characteristic curve ( ROC ) was 0.854 ( 95% confidence interval 0.732 -0.961 , P <0.01 ) . Conclusions Plasma gelsolin levels are correlated with the severity of STEMI lesions and plasma gelsolin can be used as predicting factor of prognosis .

Relationship of Tumor Necrosis Factor Genetic Polymorphisms with the Clinical Course and Outcome of Non-Hodgkin's Lymphoma / 中国肿瘤临床

Objective:To investigate the relationship of-308bp polymorphism in tumor necrosis factor-α (TNFa)gene and+252bp in lymphotoxin-α(LTα)gene with the clinical course and outcome of non-Hodgkin's lymphoma(NHL).Methods:The single base change in TNFα gene and LTα gene was analyzed among 96 Chinese patients with NHL and 72 normal controls by using PCR-restrictive fragment length polymorphism (RFLP).The clinical data were collected and survival analysis was performed.Results:In NHL patients,no statistcally significant association was found between the presence of a given TNF/LT haplotype status and clinical variables such as age,seX,disease stage,and so on.The patients carrying low-risk haplotype achieved a more sensitive response to first-line therapy than that in patients with high-risk haplotype(70.4%v 45.2%:P=0.018).The estimated 1-year progression-free survival rates in the high-risk and low-risk groups were 66.67% and 87.5%,respectively(log-rank test,P=0.0231).Kaplan-Meier method showed that the estimated 2-year and 4-year overall survival rates were 39.95%and 8.32%in patents carrying high-risk haplotypes and 65.13%and 46.52%in patients carrying low-risk haplotypes,respectively(log-rank test,P=0.0012).In multivariate Cox regression models.the TNF/LT haplotype status was found to be a dsk factor for outcome of NHL (P=0.034).Conclusion:There is an association between TNF/LT haplotype status and response to therapy and outcomes of NHL in Canton area,China.Detecting TNF/LT haplotype may be a sensitive method to evaluate the outcome of NHL.

Expression of β-catenin in patients with chronic myeloid leukemia / 中国病理生理杂志

AIM: To observe the expression of β-catenin in patients with chronic myeloid leukemia (CML) at different disease phases, and to analyze the relationship between BCR-ABL and cytogenetic response to imatinib mesylate. METHODS: RT-PCR and Western blotting were used to detect β-catenin mRNA and protein expression in bone marrow mononuclear cells (BMMNCs) from 99 patients with CML. The association with BCR-ABL and BCR-ABL fusion was determined by FISH in 94 patients after one year treatment with imatinib mesylate, and the relationship between β-catenin and cytogenetic response to imatinib mesylate was analyzed. RESULTS: The expression of β-catenin was increased significantly in patients with blast crisis and accelerated phase (P<0.01), while the expression of β-catenin between normal person and chronic phase of CML patients was not statistically different (P>0.05). No significant relation between β-catenin and BCR-ABL expression (r=0.314, P>0.05) was observed. The expression of β-catenin was increased significantly in the patients who did not reach main cytogenetic remission (P<0.01). CONCLUSION: The patients in progression phases of CML over-express β-catenin. The expression of β-catenin is not significantly related to BCR-ABL expression, but related to the therapeutic response of imatinib. Beta-catenin may be involved in the mechanism of CML progression and could be used as a new therapeutic target.

Effects of serum from myocardial infarction rats on rat bone marrow mesenchymal stem cell differentiation into cardiomyocytes / 中国组织工程研究

BACKGROUND: Differentiation of bone marrow mesenchymal stem calls(BMSCs) is associated with their microenvironment. After acute myocardial infarction (AMI), the necrosis of cardiomyocytes caused activation of complement, generation of free radical, and secretion of various cell factors. As a result, the ingredients of patients' serum also changed, so does the changes will influence the differentiation of BMSCs into cardiomyocytes? And what influence it will be? OBJECTIVE: To investigative effects of AMI rat serum on the differentiation of BMSCs into cardiomyocytes. DESIGN, TIME AND SETTING: The in vitro controlled cytology experiment was performed at the Laboratory of Center for Stem cells and Tissue Engineering, Sun Yat-sen University from September in 2005 to June in 2006. MATERIALS: SPF Sprague Dawley rats, weighing 50-80 g, aged 3-4 weeks, were used for culture of BMSCs, and SpragueDawley rats, weighing 200-300 g, aged 6-8 weeks, were used for making AMI models. METHODS: BMSCs were isolated and cultured with the adherent method. After making AMI rat models by deligating anterior descending of the left coronary artery, the serum were collected and centrifuged from AMI and normal rats. Then the passage 3 of BMSCs were divided into six groups, non-induction group, 5-azacytidine (5-aza) group, 5-aza plus serum from AMI rat group, 5-aza plus serum from normal rat group, serum from AMI rat group, and serum from normal rat group. MAIN OUTCOME MEASURES: Morphology changes in rat BMSCs after induction; Expression of cardiac troponin T of BMSCs after induction; Expression of GATA-4 and desmin mRNA of BMSCs after induction. RESULTS: After being induced by 5-aza and two kinds of serum, some cells became elongated and thinner. Two to three weeks after induction, some cells had a ball-like or rod-like appearance, and connection were formed between adjacent cells. It showed that some BMSC have differentiated into cardiac like cells. The expression of cardiac troponin T, GATA-4 and desmin were positive in cells differentiated from BMSCs. The troponin T expression in control group and simple serum induction group were negative, but GATA-4 and desmin expressed weakly. CONCLUSION: Serum from AMI rat cannot induce BMSCs to differentiate into cardiomyocytes alone, but it promotes BMSCs induced by 5-aza differentiating into cardiomyocytes and facilitates the differentiated calls into mature.

Studies on the expression of Survivin in human leukemia K562 treated by cytarabine / 白血病·淋巴瘤

Objective To investigate the influences of cytarabine on Survivin gene expression in human leukemia K562 cell line and discuss the mechanism of drug resistance in chemotherapy. Methods The IC50 of cytarabine was chosen by MTr assay. The K562 cells were exposed to certain concentration of cytarabine for about 24 hours and 48 hours. The expression levels of Survivin gene were detected by RT-PCR and Western-blot. Results After exposed to cytarabine for 24 hours and 48 hours, the Survivin mRNA level of K562 cells was significantly elevated about 1.92 and 3.38-fold, and the protein expression level was elevated about 1.92 and 2.64-fold. Conclusion An elevated expression of Survivin was tested in K562 cells treated by cytarabine. Consequently, the elevated expression of Survivin could resist apoptosis induced by chemotherapeutic agent which probably associated with chemotherapeutic drug resistance.

The influence of the PBSC collection yield by choosing the different venous accesses in the healthy donors / 中国实用护理杂志

Objective To investigate the influence of the PBSC collection yield by choosing the differ-era venous accesses in the healthy donors. Methods 118 healthy PBSC donors performing PBSC collection between January 2000 and December 2007 in our hospital were divided into four groups according to the differ-ent venous accesses. The PBSC collection yield of four groups,including mononuclear cells (MNC) count and CD34+ cells count were observed. Results In the ulnar V-ulnar V group,MNC (5.31±2.29)×108/kg,CD34+ cells (4.78±2.06)×106/kg;ulnar V- antecubital V group,MNC(5.11±2.34)×108/kg,CD34+cells(4.34±1.99)×106/kg;antecubital V- antecubital V group,MNC (5.61±1.73)±×108/kg,CD34+cells (4.60±1.42)×106/kg;ulnar V- radial V group,MNC(4.60±×1.70)×108/kg,CD34+cells (4.05±1.50)×106/kg.There was no statistical differ-ence of the PBSC collection yield between four groups (P>0.05). Conclusions Different venous accesses don't affect the PBSC collection yield in the PBSC healthy donors.

In situ transplantation of autologous bone marrow stem cells mobilized by Granulocyte colony-stimulating factor for treatment of ischemic cerebral infarction in rats / 中国组织工程研究

BACKGROUND:Granulocyte colony-stimulating factor (G-CSF) can strongly mobilize bone marrow hematopoietic stem cells (HSCs). It has been proved that G-CSF has the ability to mobilize both HSCs and mesenchymal stem cells (MSCs).OBJECTIVE:To investigate the therapeutic effect of G-CSF in mobilizing autologous bone marrow stem cells entering cerebral infarction zone on ischemic cerebral infarction in rats.DESIGN:A randomized grouping design, animal experiment.SETYING: Center for Stem Cell Biology and Tissue Engineering of Sun Yat-sen University.MATERIALS: This experiment was carried out at the Animal Experimental Department of Sun Yat-sen University (North District) and Center for Stem Cell Biology and Tissue Engineering of Sun Yat-sen University from September 2004 to January 2005. Totally 200 male Wistar rats were chosen and randomly divided into autologous bone marrow stem cells transplantation group and control group, with 100 rats in each group.METHODS:Rats of two groups were made cerebral infarction models by line occlusion. Transplantation group introduced intraperitoneal injection of 60 μg/kg G-CSF one hour after operation. The control group introduced intraperitoneal injection of saline of the same dosage at the same time. ①All rats were weighed before operation and 24 hours, 48 hours, one week after operation to evaluate body mass loss rate. They were also given neurological grading. Grading criteria: Grade 0 is normal. Grade Ⅰ is that the right forelimb bends. Grade Ⅱ is that the right forelimb grasped weakly when the tail is lifted. Grade Ⅲ is that the rat has no directivity in automatic action and circumrotates to right when the tail is lifted. Grade Ⅳ is that the rat circumrotates to right in automatic action. ②15 rats in each group were selected. 24 hours, 48 hours, one week after operation, we opened the skulls, took out the brain and used 2,3,5-Triphenyltetrazoluim Chloride (TTC) staining to measure infarction volume, hematoxylin-eosin(HE) staining to observe the pathological change , and immunohistochemistry to detect the infiltration of CD34+ cells.MAIN OUTCOME MEASURES:Body mass loss rate, neurological grade,infarction volume, pathological change and infiltration of CD34+ cells.RESULTS: Totally 180 of 200 rats were successfully made cerebral infarction model. 48 rats died in seven days after operation. As a result, 132 rat models were alive and 120 rats were randomly selected for data analysis. ①Measurement of body mass and neurological grading: There was no significant difference in body mass loss rate between two groups 24 hours and 48 hours after operation (P ＜ 0.05);one week after operation, body mass loss rate was significantly lower in transplantation group [(10.5±8.2)%]than in control group [(17.8±7.1)%] (P ＜ 0.05). There was no significant difference in neurology grade between two groups. ②Infarction volume:Infarction volume and the percent of infarction volume in the whole brain in control group were all higher than those in the transplantation group,with significant difference [ (251.69±52.77) mm3 vs(145.72±28.05)mm3,(17.00±2.69)% vs (9.90±1.62)% ,P ＜ 0.01]. ③Pathological change: 24 hours after operation, the brain tissue of two groups got classical pathological change of cerebral ischemia infarction. There were some mono-nucleus cells infiltrating in transplantation group while none in control group. 48 hours after operation, most nerve cells disappeared and the glial cells were degenerated. There were many mono-nucleus cells infiltrating in transplantation group while a few in control group. One week after operation, tissues in the infarction zone were liquescent with many monocaryons and lymphocytes infiltrating around them in control group. In transplantation group, part of the infarction zone was plerosised through proliferation of newly born capillaries and glial cells and inflammatory cells were not evident. ④Immunohistochemistry: CD34+ mono-nucleus cells were detected in the ischemic territory in transplantation group 24 hours after operation while none in the brain of other side and control group. There were CD34+ mono-nucleus cells and pyramidate cells with mutations in transplantation group 48 hours after operation while none in the brain of other side and control group.CONCLUSION:The stem cell transplantation in situ therapy, which employs self-marrow stem cells mobilized by G-CSF can relieve the ischemic degree and reduce the infarction volume.

Effect of recombinant human thrombopoietin on exsanguine thrombocytopenia mice / 中国病理生理杂志

AIM:To investigate effect of recombinant human thrombopoietin on exsanguine thrombocytopenia mice. METHODS:Normal peripheral platelet counts were performed on sample obtained from the tail vein of purebred Babl/c mice including experimental and control groups before experimentation. rhTPO was injected into the mice by intraperitoneal injection once a day for 7 days. On the seventh and the fourteenth day, the mice were phlebotomized from the supra-obitalis vein in order to make exsanguine thrombocytopenia animal model. At the same time, we observed the biological activity of recombinant human thrombopoietin in vivo and the mice's death rate. RESULTS: On the seventh day and the fourteenth day, platelet counts of mice treated by rhTPO were higher than those by PBS (P＜0.05). Moreover the platelet counts of mice in experimental group of rhTPO showed increasing tendency following experimental days. In addition, death happened in two groups after those mice were phlebotomized from the supra-obitalis vein, but the death rate in negative control group was evidently higher than that in experimental group (P＜0.05). CONCLUSION:rhTPO had obvious biological activity in increasing platelet production, which resulted in the drop in thrombocytopenia mice's death rate.

Recent advances in platelet growth factors / 中国病理生理杂志

Currently, platelet transfusion is the primary treatment for thrombocytopnia which results from intensive chemotherapy and radiotherapy of cancer. While repeated platelet transfusions are associated with several problems. The clinical availability of safe and effective platelet growth factors is eagerly awaited. Currently, a mumber of hematopoietic growth factors with thrombopoietic activity have been identified. This review discusses the biological characteristics and the clinical trial investigation development of platelet growth factors.

Effects of thrombopoietin and thrombopoietinⅡ on human platelet activation / 中国病理生理杂志

AIM:To investigate effects of thrombopoietin(TPO) and TPOⅡ on human platelet activation in vitro. METHODS:Human platelets were incubated in the phosphate-buffered saline containing rhTPO or TPOⅡ at the concentration of 100 μg/L for five minutes. In order to determine the rate of platelet activation. The CD62P and CD41 expressions on platelets were analysed by flow cytometry using fluorescence labelled monoclonal antibody to CD62P and CD41. RESULTS:The results demonstrated that expression of CD62P on platelets which were incubated with rhTPO or TPOⅡ didn't increase compared with that of contrast group. CONCLUSION:Both rhTPO and TPOⅡdidn't cause the disorder of platelet activation.

Accumulation of p53 and cytokeratin-18neo in non-small cell lung cancer and its clinicopathological significance / 中国病理生理杂志

AIM： To investigate the tumorigenicity of lung cancer by learning the accumulation of p53 and the exposure of cytokeratin 18 neo-epitope(CK-18neo) related to the clinicopathological parameters in non-small cell lung cancer(NSCLC). METHODS: To detect the monoclonal antibodies of p53 and M30 CytoDEATH(specific antibody for CK-18neo) in 62 cases of NSCLC (included 29 cases of squamous cell carcinoma and 33 cases of adenocarcinoma) and 10 cases of control group by adopting immunohistochemistry assay (LSAB). Moreover, the immunoreactivity of p53 was quantitatively evaluated with positive unit (PU). RESULTS: (1) p53 immunoreactivity was positive in 15 of 29 squamous cell carcinoma (51.72%), 15 of 33 adenocarcinoma (45.45%), 30 of 62 NSCLC (48.39%). In 10 control cases was negative. There were significant differences between these groups (P＜0.01). (2)In 62 cases of NSCLC, AI% of M30 is 1.10%, and in 29 cases of squamous cell carcinoma is 0.95%, and in 33 cases of adenocarcinoma is 1.24%. In 10 control cases, the AI% is 1.06%. There is not significant difference among these groups . (3) According to the results of Pearson's correlation analysis, we found positive linear correlation between the immunoreactivity of p53（-/+）, p53（5 degrees）and p53（PU）(P＜0.01). CONCLUSION: Our results suggested that the pathogenesis of NSCLC might be related to the mutation of gene p53 and cell excessive proliferation and insufficient apoptosis.

The expression of β2 integrins and L - selectin on acutelymophocytic leukemic cells and its clinical implications / 中国病理生理杂志

AIM and METHODS: To investigate the expression of adhesion molecule β2 integrins (CD11a、 CD11b) and L-selectin(CD62L )on Acute Lymophocyte Leukemia(ALL) cells and its Clinical Implications. Adhesion molecules CD11a、CD11b、 CD62L of 45 ALL patients and 25 health people were measured by flow - cytometric analysis. RESULTS :①CD11a and CD11b expression were lower on ALL cells than the normal hematopoietic cells. The rate of low expression was 100% for CD11b, 50% for CD11a,respectively. CD62L expression were higher on ALL cells than the normal hematopoietic cells.②The CD11a was lower expressed on B - ALL than T- ALL. CD62L was higher on T- ALL than B- ALL. ③The expression of CD11a in the invasion group was much higher than that in the non - invasive group( P < 0.05).④The levels of CD11a,CD11b were returned to normal levels at remission. CONCLUSION: These results suggest that there are abnormalities in the expression of cell adhesion molecules in ALL which may help identify ALL subtypes and the treatment effect.

The expression of ?_2 integrins and L-selectin on acute lymophocytic leukemic cells and its clinical implications / 中国病理生理杂志

AIM and METHODS: To investigate the expression of adhesion molecule ? 2 integrins (CD11a、CD11b) and L-selectin(CD62L )on Acute Lymophocyte Leukemia(ALL) cells and its Clinical Implications. Adhesion molecules CD11a、CD11b、 CD62L of 45 ALL patients and 25 health people were measured by flow-cytometric analysis. RESULTS:①CD11a and CD11b expression were lower on ALL cells than the normal hematopoietic cells. The rate of low expression was 100% for CD11b, 50% for CD11a,respectively. CD62L expression were higher on ALL cells than the normal hematopoietic cells.②The CD11a was lower expressed on B-ALL than T-ALL. CD62L was higher on T-ALL than B-ALL. ③ The expression of CD11a in the invasion group was much higher than that in the non-invasive group(P

Study of cytotoxicity of anti-CD20 monoclonal antibody against myeloma cells in vitro / 中国病理生理杂志

AIM: To observe the cytotoxicity on myeloma cells mediated by anti-CD20 monoclonal antibody-mabthera, after heightening level of CD20 expression on myeloma cells membrane by ?-interferon. METHODS: 10 untreated(UT) and 10 relapsed or refractory(RR) MM patients'myeloma cells were cultured with human recombinant ?-interferon (hr?-IFN) at concentrations of (0-800)?10~3 U/L to heighten level of CD20 expression, then complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) on myeloma cells mediated by mabthera were studied through MTT methods. RESULTS: When CD20 expression of UT MM and RR MM patients' myeloma cells increased after treated by hr?-IFN, 12 mg/L and 16 mg/L mabthera mediated ADCC and CDC (against) myeloma cells in group UT patients and group RR patients, respectively. CONCLUSION: After heightened level of CD20 expression on myeloma cells membrane by hr?-IFN, mabthera mediated ADCC and CDC against myeloma cells in vitro.

The plasticity of hematopoietic stem cells and clinical application / 中国病理生理杂志

Traditional concept has been that hematopoietic stem cells (HSC) are tissue-specific stem cells, which are restricted to generate the cell types of the blood and immune system. However, recent studies have shown that there is a higher plasticity of the HSC than previous expected, it can be induced to transdifferentiated into mature cells of other nonhematopoietic organs after transplantation in vivo. In this article, the recent advances in the plasticity of HSC and its potential clinical application are reviewed.

Study on bone marrow angiogenic mediators and inhibitors in aplastic anemia / 中国病理生理杂志

AIM: Through detecting bone marrow angiogenic mediators and inhibitors in aplastic anemia(AA) patients,the value of angionesis in AA pathogenesis was elucidated.METHODS: The patients were divided into severe AA group(SAA,8 patients),non severe AA group(NSAA,10 patients),and normal control group(7 persons),5 patients were observed before treating(group beginning) and getting improvement(group improving).The angiogenic mediators vascular endothelial growth factor(VEGF) and bFGF were detected by ELISA,angiogenic inhibitors IFN? and TSP were detected by ELISA and flow cytometry,respectively.RESULTS: The levels of VEGF were lower in SAA group and NSAA group than those in control group significantly(P

Effects of Bene Jones protein and TGF-?_1 on the proliferation of rat renal proximal tubular cells in vitro / 中国病理生理杂志

AIM: To study the effect of Bene Jones protein (BJP) from multiple myeloma(MM) patient and TGF-? 1 on cultured renal proximal tubular cell(PTC) proliferation. METHODS:[ 3H] TdR incorporation was used to study the effect of ?BJP and TGF-? 1 on cultured rat NRK.52E PTC proliferation,the expression of TGF-? 1 in the supernatant of PTC cultured with BJP was assessed with ELISA. RESULTS:① [ 3H] TdR incorporation of PTC was inhibited by BJP in a dose-dependent manner,when co-cultured with 100-800 ?mol/L BJP and 2.0 ?g/L TGF-? 1, the [ 3H] TdR incorporation was lower than that of BJP alone, especially when BJP≥400 ?mol/L; ②The expression of TGF-? 1 in the supernatant of PTC cultured with BJP was increased ,especially when BJP≥400 ?mol/L( P

Intervention therapy of MDS / 肿瘤研究与临床

Myelodysplastic syndromes(MDS) is a malignant disease of hematopoietic stem cell / progenitor cell clones. Therapies of MDS including immuno-suppressive drugs, chemotherapy, hemopoietic stem cell transplantation and drugs suppressing malignant clones have improved much in recent years. This review is about intervention therapy of MDS and the therapy effect.

Accumulation of p53 and cytokeratin-18neo in non-small cell lung cancer and its clinicopathological significance / 中国病理生理杂志

AIM: To investigate the tumorigenicity of lung cancer by learning the accumulation of p53 and the exposure of cytokeratin 18 neo-epitope(CK-18neo) related to the clinicopathological parameters in non-small cell lung cancer(NSCLC). METHODS: To detect the monoclonal antibodies of p53 and M 30 CytoDEATH(specific antibody for CK-18neo) in 62 cases of NSCLC (included 29 cases of squamous cell carcinoma and 33 cases of adenocarcinoma) and 10 cases of control group by adopting immunohistochemistry assay (LSAB). Moreover, the immunoreactivity of p53 was quantitatively evaluated with positive unit (PU). RESULTS: (1) p53 immunoreactivity was positive in 15 of 29 squamous cell carcinoma (51.72%), 15 of 33 adenocarcinoma (45.45%), 30 of 62 NSCLC (48.39%). In 10 control cases was negative. There were significant differences between these groups ( P